Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

20 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Trastuzumab deruxtecan in HER2-positive metastatic breast cancer and beyond.
Perez J, Garrigós L, Gion M, Jänne PA, Shitara K, Siena S, Cortés J. Perez J, et al. Among authors: garrigos l. Expert Opin Biol Ther. 2021 Jul;21(7):811-824. doi: 10.1080/14712598.2021.1890710. Epub 2021 Apr 1. Expert Opin Biol Ther. 2021. PMID: 33759669 Free article.
Trastuzumab deruxtecan in patients with central nervous system involvement from HER2-positive breast cancer: The DEBBRAH trial.
Pérez-García JM, Vaz Batista M, Cortez P, Ruiz-Borrego M, Cejalvo JM, de la Haba-Rodriguez J, Garrigós L, Racca F, Servitja S, Blanch S, Gion M, Nave M, Fernández-Abad M, Martinez-Bueno A, Llombart-Cussac A, Sampayo-Cordero M, Malfettone A, Cortés J, Braga S. Pérez-García JM, et al. Among authors: garrigos l. Neuro Oncol. 2023 Jan 5;25(1):157-166. doi: 10.1093/neuonc/noac144. Neuro Oncol. 2023. PMID: 35639825 Free PMC article. Clinical Trial.
Prognostic impact of CD133 expression in Endometrial Cancer Patients.
Mancebo G, Sole-Sedeno JM, Pino O, Miralpeix E, Mojal S, Garrigos L, Lloveras B, Navarro P, Gibert J, Lorenzo M, Aran I, Carreras R, Alameda F. Mancebo G, et al. Among authors: garrigos l. Sci Rep. 2017 Aug 9;7(1):7687. doi: 10.1038/s41598-017-08048-0. Sci Rep. 2017. PMID: 28794448 Free PMC article.
Phase III study to evaluate patient's preference of subcutaneous versus intravenous trastuzumab in HER2-positive metastatic breast cancer patients: Results from the ChangHER study (GEICAM/2012-07).
Ciruelos EM, Montaño A, Rodríguez CA, González-Flores E, Lluch A, Garrigós L, Quiroga V, Antón A, Malón D, Chacón JI, Velasco M, Gonzalez-Cortijo L, Jolis L, Echarri MJ, Muñoz M, Pascual T, Amigo Y, Casas M, Carrasco E, Casas A. Ciruelos EM, et al. Among authors: garrigos l. Eur J Cancer Care (Engl). 2020 Jul;29(4):e13253. doi: 10.1111/ecc.13253. Epub 2020 Jun 23. Eur J Cancer Care (Engl). 2020. PMID: 32578279 Clinical Trial.
AI-related BMD variation in actual practice conditions: A prospective cohort study.
Rodríguez-Sanz M, Prieto-Alhambra D, Servitja S, Garcia-Giralt N, Garrigos L, Rodriguez-Morera J, Albanell J, Martínez-García M, González I, Diez-Perez A, Tusquets I, Nogués X. Rodríguez-Sanz M, et al. Among authors: garrigos l. Endocr Relat Cancer. 2016 Apr;23(4):303-12. doi: 10.1530/ERC-16-0025. Epub 2016 Feb 24. Endocr Relat Cancer. 2016. PMID: 26911377
20 results